Description:

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Post-Treatment Assessments

Link:
https://clinicaltrials.gov/ct2/show/NCT00373425
Keywords:
  1. 7/27/16 7/27/16 -
  2. 8/1/16 8/1/16 -
  3. 9/27/16 9/27/16 -
Uploaded on:

September 27, 2016

DOI:
To request one please log in.
License :
Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Post-Treatment Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425

Post-Treatment Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

Vital Assessment
kg
Physical Examination
Pregnancy Test
Was pregnancy test performed?
Pregnancy Test: Not Applicable
Biochemistry/Proteomics
Reason Off Treatment
Reason Off Treatment
Death
Did the patient die before the Post-treatment visit?
Primary Cause of Death
Was an autopsy performed?
Investigator Signature

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial